C07K 14/7455
Thrombomodulin
Official title: {Thrombomodulin}
C07K14/7455 (Thrombomodulin) appears on 57 US grants and 51 published applications in this corpus.
Search patents in C07K- Granted patents
- 57
- Published applications
- 51
- Assignees
- 34
- Inventors
- 145
- Latest grant
- 9 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 2 | 0 |
| 1992 | 0 | 0 |
| 1993 | 3 | 0 |
| 1994 | 3 | 0 |
| 1995 | 2 | 0 |
| 1996 | 3 | 0 |
| 1997 | 2 | 0 |
| 1998 | 3 | 0 |
| 1999 | 1 | 0 |
| 2000 | 2 | 0 |
| 2001 | 1 | 0 |
| 2002 | 2 | 0 |
| 2003 | 1 | 2 |
| 2004 | 3 | 1 |
| 2005 | 0 | 3 |
| 2006 | 1 | 0 |
| 2007 | 1 | 1 |
| 2008 | 1 | 3 |
| 2009 | 2 | 1 |
| 2010 | 2 | 6 |
| 2011 | 2 | 5 |
| 2012 | 3 | 1 |
| 2013 | 2 | 3 |
| 2014 | 0 | 4 |
| 2015 | 4 | 4 |
| 2016 | 2 | 1 |
| 2017 | 0 | 2 |
| 2018 | 0 | 1 |
| 2019 | 0 | 1 |
| 2020 | 1 | 0 |
| 2021 | 2 | 2 |
| 2022 | 0 | 2 |
| 2023 | 1 | 3 |
| 2024 | 0 | 2 |
| 2025 | 0 | 1 |
| 2026 | 3 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Multitransgenic pigs comprising ten genetic modifications for xenotransplantation9 Jun 2026US 12,648,548 B2Revivicor, Inc.
- Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance26 May 2026US 12,637,690 B2eGenesis, Inc.
- Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance19 May 2026US 12,630,838 B2eGenesis, Inc.
- Fusion proteins and antibodies targeting human red blood cell antigens18 Apr 2023US 11,629,198 B2The Trustees of the University of Pennsylvania
- Thrombin-thrombomodulin fusion proteins as a powerful anticoagulant10 Aug 2021US 11,085,031 B2Saint Louis University
- Multitransgenic pigs comprising ten genetic modifications for xenotransplantation18 Jun 2026US 2026/0165304 A1Revivicor, Inc.
- Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance9 Apr 2026US 2026/0098278 A1eGenesis, Inc.
- Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance13 Nov 2025US 2025/0346918 A1eGenesis, Inc.
- Compositions and methods for treating osteoarthritis using a cd14 inhibitor18 Jul 2024US 2024/0239913 A1
- Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance14 Mar 2024US 2024/0084322 A1eGenesis, Inc.
Most cited
By later US patents
- Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders57US 6,818,439 B1Chiron Corporation · 2004
- Expression and purification of recombinant soluble tissue factor37US 5,298,599 AOklahoma Medical Research Foundation · 1994
- Oxidation resistant thrombomodulin analogs30US 5,256,770 ASchering Corporation · 1993
- Superior thrombomodulin analogs for pharmaceutical use28US 5,466,668 ASchering Corporation · 1995
- Protease-resistant thrombomodulin analogs24US 5,827,824 ASchering Corporation · 1998